Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: Evidence from a randomized trial in Uganda

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chang, Hsiao Han ^a   Meibalan, Elamaran ^a   Zelin, Justin ^a   Daniels, Rachel ^a,b   Eziefula, Alice C ^c   Meyer, Evan C ^a   Tadesse, Fitsum ^c   Grignard, Lynn ^d   Joice, Regina C ^a   Drakeley, Chris ^c   Wirth, Dyann F ^b,e   Volkman, Sarah K ^a,b,d   Buckee, Caroline ^a   Bousema, Teun ^c,e   Marti, Matthias ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d SIMMONS COLLEGE   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; PRIMAQUINE; PROTOZOAL DNA;

CHILD; COMBINATION DRUG THERAPY; DRUG EFFECT; DRUG RESISTANCE; GENETICS; GENOTYPE; HUMAN; INFANT; MALARIA FALCIPARUM; PARASITOLOGY; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; UGANDA;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GENOTYPE; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; PRIMAQUINE; REAL-TIME POLYMERASE CHAIN REACTION; UGANDA;

EID: 84971016764     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26330     Document Type: Article

References (33)

1. Organization, W. H. World Malaria Report 2014 (2014).
2. Moonen, B. et al. Operational strategies to achieve and maintain malaria elimination. Lancet 376, 1592-1603, doi: 10.1016/S0140-6736(10)61269-X (2010).
3. Drugs, M. C. G. O. A research agenda for malaria eradication: drugs. PLoS medicine 8, e1000402, doi: 10.1371/journal.pmed.1000402 (2011).
4. White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrobial agents and chemotherapy 41, 1413-1422 (1997).
5. Adjuik, M. et al. Artesunate combinations for treatment of malaria: meta-Analysis. Lancet 363, 9-17 (2004).
6. Ashley, E. A. et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. The New England journal of medicine 371, 411-423, doi: 10.1056/NEJMoa1314981 (2014).
7. Four Artemisinin-Based Combinations Study, G. A head-To-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: A randomized trial. PLoS medicine 8, e1001119, doi: 10.1371/journal.pmed.1001119 (2011).
8. Beshir, K. B. et al. Residual Plasmodium falciparum parasitemia in Kenyan children after artemisinin-combination therapy is associated with increased transmission to mosquitoes and parasite recurrence. J Infect Dis 208, 2017-2024, doi: 10.1093/infdis/jit431 (2013).
9. Gosi, P. et al. Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia. Malar J 12, 403, doi: 10.1186/1475-2875-12-403 (2013).
10. Teuscher, F. et al. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. J Infect Dis 202, 1362-1368, doi: 10.1086/656476 (2010).
11. Klonis, N. et al. Altered temporal response of malaria parasites determines differential sensitivity to artemisinin. Proceedings of the National Academy of Sciences of the United States of America 110, 5157-5162, doi: 10.1073/pnas.1217452110 (2013).
12. Joice, R. et al. Inferring developmental stage composition from gene expression in human malaria. PLoS Comput Biol 9, e1003392, doi: 10.1371/journal.pcbi.1003392 (2013).
13. Eziefula, A. C. et al. Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: A randomised, controlled, double-blind, dose-ranging trial. The Lancet. Infectious diseases 14, 130-139, doi: 10.1016/S1473-3099(13)70268-8 (2014).
14. Okell, L. C. et al. Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using modelbased cost-effectiveness analysis. Nat Commun 5, 5606, doi: 10.1038/ncomms6606 (2014).
15. Daniels, R. et al. A general SNP-based molecular barcode for Plasmodium falciparum identification and tracking. Malar J 7, 223, doi: 1475-2875-7-223 (2008).
16. Carlsson, A. M. et al. Plasmodium falciparum population dynamics during the early phase of anti-malarial drug treatment in Tanzanian children with acute uncomplicated malaria. Malar J 10, 380, doi: 10.1186/1475-2875-10-380 (2011).
17. Betson, M. et al. Detection of persistent Plasmodium spp. infections in Ugandan children after artemether-lumefantrine treatment. Parasitology 141, 1880-1890, doi: 10.1017/S003118201400033X (2014).
18. Nassir, E. et al. Impact of genetic complexity on longevity and gametocytogenesis of Plasmodium falciparum during the dry and transmission-free season of eastern Sudan. International journal for parasitology 35, 49-55, doi: 10.1016/j.ijpara.2004.10.014 (2005).
19. Abdel-Wahab, A. et al. Dynamics of gametocytes among Plasmodium falciparum clones in natural infections in an area of highly seasonal transmission. J Infect Dis 185, 1838-1842, doi: JID011146 (2002).
20. White, N. J. The parasite clearance curve. Malar J 10, 278, doi: 10.1186/1475-2875-10-278 (2011).
21. Bousema, T. & Drakeley, C. Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clinical microbiology reviews 24, 377-410, doi: 10.1128/CMR.00051-10 (2011).
22. Ouedraogo, A. L. et al. The plasticity of Plasmodium falciparum gametocytaemia in relation to age in Burkina Faso. Malaria journal 9, 281, doi: 10.1186/1475-2875-9-281 (2010).
23. Yeka, A. et al. Artesunate/Amodiaquine Versus Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria in Uganda: A Randomized Trial. J Infect Dis 213, 1134-1142, doi: 10.1093/infdis/jiv551 (2016).
24. Kapisi, J. et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens. Malar J 14, 53, doi: 10.1186/s12936-015-0583-9 (2015).
25. Bretscher, M. T. et al. Detectability of Plasmodium falciparum clones. Malar J 9, 234, doi: 10.1186/1475-2875-9-234 (2010).
26. de Vries, P. J. & Dien, T. K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 52, 818-836 (1996).
27. Joice, R. et al. Plasmodium falciparum transmission stages accumulate in the human bone marrow. Science translational medicine 6, 244re245, doi: 10.1126/scitranslmed.3008882 (2014).
28. Koepfli, C. et al. How much remains undetected? Probability of molecular detection of human Plasmodia in the field. PLoS One 6, e19010, doi: 10.1371/journal.pone.0019010 (2011).
29. Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673-675 (1976).
30. Fivelman, Q. L. et al. Improved synchronous production of Plasmodium falciparum gametocytes in vitro. Mol Biochem Parasitol 154, 119-123 (2007).
31. Lambros, C. & Vanderberg, J. P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. The Journal of parasitology 65, 418-420 (1979).
32. Mueller, I. et al. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proceedings of the National Academy of Sciences of the United States of America 109, 10030-10035, doi: 10.1073/pnas.1200841109 (2012).
33. Mharakurwa, S. et al. Pre-Amplification methods for tracking low-grade Plasmodium falciparum populations during scaled-up interventions in Southern Zambia. Malar J 13, 89, doi: 10.1186/1475-2875-13-89 (2014).